Chronic Myelogenus Leukemia

Chronic Myelogenus Leukemia (CML) is a slowly advancing disease characterized by the clonal expansion of myeloid precursors in the bone marrow and consequential displacement of normal hematopoietic cells.


Molecular Assays:

BCR-ABL: The BCR-ABL fusion is found in 95% of CML cases and is associated with a very poor prognosis. Detection of the BCR-ABL translocation aids researchers in the classification of disease, prognosis, response to treatment, and the assessment of minimal residual disease (MRD).1,2,3


FISH Assays:

Trisomy 8: Trisomy 8 is the most common genetic instability associated with the progression of CML chronic phase to blast crisis.4

Order FISH Probes


    1. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Müller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ES, Press RD, Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NC. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010 Nov 25;116(22):e111-7. Epub 2010 Aug 18.
    2. WHO International Standard. 1st WHO International Genetic Reference Panel for quantitation of BCR-ABL translocation by RQ-PCR.
    3. Hughes T, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
    4. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004 Jun 1;103(11):4010-22. Epub 2004 Feb 24. Review. PubMed PMID: 14982876.